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Enzyme activities localized in the luminal compartment of the endoplasmic reticulum are integrated into the cellular metabolism by
transmembrane fluxes of their substrates, products and/or cofactors. Most compounds involved are bulky, polar or even charged; hence, they
cannot be expected to diffuse through lipid bilayers. Accordingly, transport processes investigated so far have been found protein-mediated. The
selective and often rate-limiting transport processes greatly influence the activity, kinetic features and substrate specificity of the corresponding
luminal enzymes. Therefore, the phenomenological characterization of endoplasmic reticulum transport contributes largely to the understanding of
the metabolic functions of this organelle. Attempts to identify the transporter proteins have only been successful in a few cases, but recent
development in molecular biology promises a better progress in this field.
© 2007 Elsevier B.V. All rights reserved.Keywords: Nucleotide sugar transporters; Solute carrier family 35; Glucose 6-phosphate translocase; TAP; Translocon; PermeabilityContents
1. Transported molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
1.1. Sugars and derivatives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
1.1.1. Glucose. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
1.1.2. Ascorbate/dehydroascorbate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
1.1.3. Glucose 6-phosphate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
1.2. Phosphate and sulfate ions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1329
1.3. Nucleotide sugars and derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1329Abbreviations: ER, endoplasmic reticulum; SER, smooth ER; RER, rough ER; EST, expressed sequence tags; DIDS, 4,4′-diisothiocyanostilbene-2,2′-disulfonic
acid; NEM, N-ethylmaleimide; G6Pase, glucose 6-phosphatase; PDI, protein disulfide isomerase; G6P, glucose 6-phosphate; H6PDH, hexose 6-phosphate
dehydrogenase; 11β-HSD1, 11β-hydroxysteroid dehydrogenase type 1; GSD1, glycogen storage disease type 1; G6PT, G6P translocase; vG6PT, variant G6P
translocase; SR, sarcoplasmic reticulum; NaPi or NPT, sodium/phosphate transporter; UDP, uridine diphosphate; UDP-Glc, UDP-glucose; UDP-GlcNAc, UDP-N-
acetylglucosamine; UDP-Gal, UDP-galactose; UDP-GalNAc, UDP-N-acetylgalactosamine; UDP-Xyl, UDP-xylose; NSTs, nucleotide sugar transporters; SLC35,
solute carrier family 35; Glc, glucose; Man, mannose; GlcNAc, N-acetylglucosamine; UGGT, UDP-Glc glycoprotein glucosyltransferase; UGTrel1 (SLC35B1), UDP-
Gal transporter related protein 1; AtUTr1, Arabidopsis thaliana UDP-Gal/UDP-Glc transporter; UDP-GlcA, UDP-glucuronic acid; SITS, 4-acetamido-4′-
isothiocyanostilbene-2,2′-disulfonic acid; DEPC, diethyl pyrocarbonate; UGTrel7 (SLC35D1), UDP-Gal transporter related protein 7; UGT, UDP-glucuronosyl-
transferase; Ero1p, endoplasmic reticulum oxidoreductin 1 protein; Erv1p, essential for respiration and viability 1 protein; Fmo1p, flavin-containing monooxygenase;
Flc, flavin carrier; CoA, coenzyme-A; Ac-CoA, acetyl-CoA; AT-1, Ac-CoA transporter; STS, steroid sulfatase; ARSC, arylsulfatase C; ES, estrone sulfatase; GSH,
glutathione; GSSG, glutathione disulfide; RyR1, ryanodine receptor type 1; MHC, major histocompatibility complex; TAP, transporter associated with antigen
processing; HEPES, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid
⁎ Corresponding author. Tel.: +36 1 2662615; fax: +36 1 2662615.
E-mail address: banhegyi@puskin.sote.hu (G. Bánhegyi).
0005-2736/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2007.03.009
1326 M. Csala et al. / Biochimica et Biophysica Acta 1768 (2007) 1325–13411.3.1. UDP-glucose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1330
1.3.2. UDP-galactose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1330
1.3.3. UDP-xylose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1331
1.3.4. UDP-glucuronic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1331
1.3.5. UDP-N-acetylglucosamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1332
1.3.6. UDP-N-acetylgalactosamine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1332
1.4. Adenine nucleotides and dinucleotides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1332
1.4.1. ATP/ADP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1332
1.4.2. NAD+/NADP+ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333
1.4.3. FAD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333
1.5. Acetyl-CoA and carnitine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333
1.5.1. Acetyl-CoA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333
1.5.2. Carnitine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333
1.6. Conjugates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
1.7. Oligopeptides. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
1.7.1. Glutathione . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
1.7.2. Antigenic oligopeptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335
2. Non-specific transport in the ER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335
3. Conclusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1336
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1336
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1336The endoplasmic reticulum (ER) is a membrane network [1]
found in every nucleated cell. The morphologically distinct
smooth and rough ER (SER and RER) are formed by the same
continuous membrane as the nuclear envelope. Its internal
compartment, the ER lumen, is completely separated from the
cytosol. However, the luminal enzyme activities related to
carbohydrate metabolism, biotransformation, steroid metabo-
lism and protein processing [2] are integrated in the cellular
metabolism, and strongly connected to the cytosolic processes.
This compartmentation often narrows the specificity of luminal
enzymes because several potential substrates cannot pass the
barrier. The transport of selected substrates across the ER
membrane is an additional point where the enzyme activity can
be potentially regulated. It is, therefore, doubtless that the ER
functions cannot be properly revealed without understanding the
related transport processes, which, in turn, requires the
identification of the participating membrane proteins. Certain
proteins involved in transport processes across ER membrane
have been molecularly identified. Nonetheless, for the majority
of the molecules that admittedly cross the ER membrane the
involved transport protein(s) are still molecularly undefined,
which is probably due to technical difficulties. The classic
strategy based on separation, purification and fractional
reconstitution of solubilized ER membrane proteins did not
lead to the expected success, with the exception of the translocon
pore components. Screening cDNA libraries or EST databases
for homologues of previously cloned transporters seems to be a
more fruitful approach. Although some transport activities have
only been characterized functionally, our knowledge about the
trans-membrane traffic in the ER is growing gradually. This
review focuses on the ER transport activities, which connect
luminal and extraluminal metabolic processes by facilitating
substrate and product fluxes. Our aim was to provide a summary
of the available information in the field.1. Transported molecules
1.1. Sugars and derivatives
1.1.1. Glucose
The assumption that glucose crosses the microsomal
membrane by simple diffusion [3] proved false and it has
become clear that glucose is unable to cross cellular
membranes. There are two possible routes for glucose generated
in the ER lumen to be exported to the blood. It has not been
clarified whether glucose leaves the cell by vesicular transport
or it is secreted through two consecutive transport steps through
the ER and plasma membranes.
Glucose transporters known at molecular level are integral
proteins of the plasma membrane. Facilitated transport of
glucose across the plasma membrane is catalyzed by a family of
proteins referred to as GLUTs. At least 12 GLUT isoforms are
known [4], having different kinetic properties, specificity and
tissue distribution.
Much less is known about glucose transport across the ER
membrane. The existence of a microsomal facilitative transport
system – different from GLUTs – was confirmed in several
ways. Meissner and Allen [5] studied glucose transport in rat
liver microsomes using rapid filtration technique. Pre-loaded
microsomes released 70% of glucose within 20 s. Nevertheless,
about 30% of microsomes showed a much lower glucose
permeation rate (t1/2=3 min). It was concluded that the
existence of microsomal vesicles with different permeability
properties could be due to the restricted number of glucose
channels in the ER.
Two components of the heterogeneous glucose transport
were characterized in rat liver microsomes [6]. The dominant
rapid phase of glucose transport had a t1/2 of a few seconds and
it was inhibited by pentamidine, cytochalasin B and 4,4′-
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slow component of glucose traffic [6] reached the steady-state
level in 10 min and became saturable at around 100 mM glucose
concentration. It was inhibited by the thiol alkylating agent N-
ethylmaleimide (NEM), but not by the inhibitors of the rapid
transport (pentamidine or cytochalasin B).
The fluctuations of glucose concentration in the cytosol and
in the ER lumen of HepG2 cells were detected in situ, by using
fluorescence resonance energy transfer-based nanosensors [8].
The steady-state glucose levels or the kinetics of glucose uptake
in these two compartments were similar, indicating the presence
of a high-capacity, bidirectional glucose transporter in the ER
membrane. However, the different sensitivity to cytochalasin B
and the different relative kinetics for galactose uptake and
release suggests that distinct proteins facilitate glucose traffic in
the plasma membrane and ER membrane.
Skepticism about the existence of the ER glucose transport is
supplied by the fact that genetic deficiency of the ER glucose
transporter has not been unequivocally demonstrated. An
alternative model for the glucose export from the ER was
suggested on the basis of findings in GLUT2 homozygous
knockout mice [9]. These mice showed normal hepatic glucose
production indistinguishable from the glucose efflux observed
in the wild-type. The proposed glucose export pathway was
temperature-sensitive, not inhibitable by cytochalasin B or by
intracellular traffic inhibitors, such as brefeldin A and
monensin, but sensitive to progesterone, which is known to
slow down exocytosis [10]. This study was broadened with
further experiments on GLUT2-null hepatocytes by pulse-
labeling technique [11]. In control and GLUT2-deficient
hepatocytes a constant fast release of glucose was observed
with similar rate, even though the GLUT2-null cells accumu-
lated glucose in their cytosol. This rapid glucose release could
be impaired by the addition of nocodazole, which causes
microtubule disruption, progesterone or low temperature.
Glucose export from the cytosol proceeds at a slower rate,
and was inhibited by phloretin and low temperature. These data
indicate the coexistence of two glucose-export pathways: the
major pathway that releases glucose through a vesicular
transport, while a separated minor pathway that relies on a
facilitated diffusion process. However, the existence of the
vesicular transport mechanism is still controversial [12]. It was
shown that nocodazole inhibits glucose transport directly, via a
microtubule independent pathway in adipocytes.
Surprisingly, it was also reported that glucose is unable to
cross the microsomal membrane [13]. This striking interpreta-
tion was presumably due to the use of mannitol as a postulated
extravesicular space marker, however it was evidenced that
mannitol penetrates the ER membrane [7].
Although a great amount of evidence support the existence
and functional role of an ER glucose transporter, it still remains
to be identified. Waddell et al. [14] described a 52-kDa protein
in rat liver microsomes, which was identified as a glucose
transporter protein, because it cross-reacted with an antibody
raised against the human erythrocyte glucose transporter and it
weakly bound cytochalasin B. This microsomal protein was
then purified and antiserum was raised against it. The antiseruminhibited glucose 6-phosphatase (G6Pase) activity and glucose
release from microsomes; hence this 52 kDa protein was
thought to be T3, the glucose transporter of the G6Pase system.
Rat liver cDNA library was also screened using this antiserum
[15]. The isolated clone showed a sequence similarity with the
members of GLUT family. The 52-kDa protein was, therefore,
termed GLUT7. Its comparison with GLUT2 revealed three
regions where the amino acid sequences of the two proteins
were identical and six extra amino acids in GLUT7 containing
an ER retention signal, which strongly suggested that the
protein resided in the ER membrane. However, this work was
retracted later, and the clone termed GLUT7 was judged as a
cloning artifact [16].
1.1.2. Ascorbate/dehydroascorbate
Ascorbate-dependent enzymatic reactions are present in the
lumen of the ER (e.g. prolyl hydroxylases). Since ascorbate –
even in species able to synthesize this molecule – is produced
only in the liver or kidney, transport system(s) are needed to
satisfy the cofactor demand of these enzymes [17]. Although
the ER ascorbate/dehydroascorbate transporter is unknown at
molecular level, functional studies in rat liver microsomes
revealed the existence of a preferential protein-facilitated
diffusion of dehydroascorbate. Dehydroascorbate uptake is
cis-inhibited and trans-stimulated by glucose and affected by
glucose transport inhibitors, which indicates the possible
involvement of a yet unidentified hexose transporter. The
presence of intravesicular reducing compounds increases,
while extravesicular reducing environment decreases dehy-
droascorbate influx [18]. The uptake of ascorbate shows
similar time course to its oxidation in rat liver microsomal
vesicles: a rapid burst phase followed by a slower process,
which suggests that it enters the vesicles after being oxidized
to dehydroascorbate. This assumption is further supported by
the findings that ascorbate influx is effectively hindered by
certain inhibitors of ascorbate oxidation (proadifen, econazole
or quercetin) [19].
Dehydroascorbate taken up by the ER can be reduced back to
ascorbate at the expense of glutathione [20] or protein thiols
[21,22]. Both reactions can be catalyzed by the luminal protein
disulfide isomerase (PDI). Ascorbate entrapped in the lumen
can leave the cell through the secretory pathway, and contribute
to the maintenance of vitamin C level in the blood [23].
1.1.3. Glucose 6-phosphate
Glucose 6-phosphate (G6P) is the substrate for at least two
enzymes in the ER lumen: G6Pase [for review, see 24] and
hexose 6-phosphate dehydrogenase (H6PDH) [24–26]. G6Pase
is present in cells capable of glucose production. It plays a
crucial role in blood glucose homeostasis because it generates
glucose by hydrolyzing G6P derived either from glycogenolysis
or gluconeogenesis. The enzyme is a membrane-bound protein
in the ER [27], and its catalytic site is localized in the lumen of
this organelle [28–32]. H6PDH is a ubiquitous microsomal
enzyme and it was shown to regulate the redox state of pyridine
nucleotides within the ER [33]. By this means, it supplies
NADPH to 11β-hydroxysteroid dehydrogenase type 1 (11β-
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pre-receptorial activation of glucocorticoids [36].
The consensus that G6P transport across the ERmembrane is
required for both G6Pase and H6PDH activities was a result of
long debate. According to the “conformational hypothesis” of
G6Pase [37,38], transport of G6P is not required to explain the
latency and specificity of the enzyme activity in native
microsomes. In contrast, the “substrate transport hypothesis”,
forwarded three decades ago, postulated the existence of a
highly specific G6P translocase, termed T1, in the ER/
microsomal membrane [39]. The “substrate transport hypoth-
esis” has been supported by a variety of experimental [3,32,40–
42] and pathological [43–45] evidence. However, the final
decisive evidence was provided when a transmembrane ER
protein that allows the entry of G6P in the luminal space was
molecularly identified [46]. In addition, it is presently well
established that ER G6P transport is also a prerequisite for
H6PDH activity [33,34,42], and indirectly for the cortisone
reductase activity of 11β-HSD1 [33–35]. Accordingly, trans-
port of G6P could be demonstrated in ER-derived vesicles
(microsomes) from practically all cell types investigated so far.
Phenomenological characterization of G6P transport in liver
microsomes revealed a bidirectional facilitated diffusion with
high capacity and low affinity [40,42]. The observed high
capacity reflects a relatively high number of transporters per
membrane surface unit in the liver ER. These features of G6P
transport are in accordance with the similar kinetic parameters
of G6Pase, which make the system able to produce glucose at a
sufficient rate to maintain blood glucose level. In contrast,
H6PDH has a relatively high affinity (Km=5 μM) to G6P
[33,34,42]. The balance between passive G6P uptake and
luminal hydrolysis determines the size of a metabolically active
microsomal G6P pool [41]. Microsomal G6P transport is
inhibited by a variety of compounds, including the anion
transport inhibitor DIDS [40,47,48], thiol reagents [49],
mercaptopicolinic acid [50], certain protease inhibitors (i.e.
tosyl-lysyl chloromethane and tosylphenylalanylchloro-
methane) [51], fatty acids [44], acyl-CoAs [52,53], hydroxyni-
trobenzaldehyde [54], chlorogenic acid and its derivates [54–
57]. Chlorogenic acid derivates, such as S3483, are particularly
powerful (Ki =1 μM) and highly selective, thus, became useful
experimental tools in G6P-transport-related studies [e.g. 32–
34,42,58].
Genetic deficiency of G6Pase activity was already described
in the 1950s [59], and termed type 1 glycogen storage disease
(GSD1). It was discovered later that liver microsomes prepared
from certain GSD1 patients contained functional G6Pase
enzyme. In these cases, G6Pase activity was found to be
reduced only when it was measured in native microsomes, while
it was normal after membrane disruption [43,44]. It was
concluded that genetic deficiency of a putative G6P transporter
can also result in GSD1 phenotype [43,44]. Hence, two
subtypes of GSD1 were distinguished: GSD1a caused by
G6Pase enzyme defect and GSD1b caused by G6P transporter
defect. Accordingly, little or no G6P transport activity was
measured in liver microsomes obtained from GSD1b patients
[45]. Defective G6P transport leads to insufficient substratesupply to G6Pase in gluconeogenic tissues; therefore, it mimics
the true enzyme deficiency. Moreover, metabolic derangement
is accompanied by neutropenia and functional defects of
polymorphonuclear leukocytes and monocytes in GSD1b
patients [24]. In fact, polymorphonuclear leukocytes from
GSD1b patients exhibit impaired chemotaxis as well as
diminished respiratory burst and phagocytotic activities.
Chemical inhibition of G6P transport with S3483 mimicked
some leukocyte defects of GSD1b patients and resulted in
apoptosis of human neutrophils [58]. It was hypothesized that
G6P transport may have a role in the antioxidant defense of
neutrophils [58].
The cDNA sequence coding the human ER G6P translocase
(G6PT) was discovered on the basis of homology with a
bacterial hexose-phosphate transporter [46]. Human G6PT is a
single copy gene consisting of 9 exons spanning approximately
5.3 kb DNA [60–62], at chromosome 11q23 [60,63]. Homo-
zygous mutant G6PT has been found in more than 95% of the
investigated GSD1b patients and at least 80 separate G6PT
mutations have been described in 117 GSD 1 patients [see 64
for a recent review]. Murine and rat cDNA sequences coding
G6PT share 93–95% homology with the human sequence [65],
and the pathology of GSD1b has been essentially reproduced in
G6PT−/− mice [66,67].
G6P uptake was investigated in microsomes prepared from
COS-1 cells over expressing human G6PTs. Microsomes were
incubated with [14C]G6P and luminal accumulation of radio-
activity was detected. Isotope accumulation was only evident
when the cells were co-transfected for the G6Pase enzyme [61],
thus, it was concluded – as previously suggested [65,68] – that
G6Pase protein was somehow required for the G6PT activity.
Nevertheless, this indirect measurement of G6P uptake does not
prove the hypothesized regulatory relationship between G6PT
and G6Pase. It is now clear that in the presence of G6Pase, the
majority of luminal radioactivity is [14C]glucose retained even
by liver microsomal vesicles [41]. An evident microsomal
transport of G6P was subsequently observed in COS-7 cells
expressing human G6PT, but not the G6Pase enzyme [69].
Northern blot analysis revealed at least two G6PT mRNAs.
The “liver”mRNA contains eight out of nine exons (without exon
7) and “brain” mRNA contains all the nine exons [70]. The latter
one was also found in heart and skeletal muscle [62,71] and
named “variant” vG6PT [71]. ThemRNAencodingG6PT ismost
abundant in liver and kidney, but is also present at lower levels in
various other tissues including, large intestine, small intestine,
stomach, testis and neutrophils [46,62,70–73]. As mentioned
above, vG6PT is expressed in brain, heart, and skeletal muscle.
Predicted Mw of human G6PT protein is approximately
46 kDa, while human vG6PT protein should contain 22
additional amino acids coded by exon 7. Western blot analysis
using an antibody against the N-terminal 17 amino acids of
G6PT revealed a liver microsomal protein, termed P46, but its
apparent Mw was not reported [74]. A FLAG-tagged protein
overexpressed in COS-1 cells, transfected with the human liver
cDNA coding G6PT, appeared to have an Mw of 37 kDa [75].
Subsequently, antibodies to hydrophilic peptide sequences of
human G6PT protein have been produced [69]. Using this
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migrate in SDS PAGE with an apparent Mw of 33 kDa [69].
Several lines of evidence, however, indicate that its real Mw is
46 kDa, and the observed unorthodoxmigration of G6PT protein
in SDS-PAGE is admittedly due to its high hydrophobicity [69].
G6PT was also immunodetected in kidney microsomes, but not
in microsomes derived from human fibrocytes, rat spleen and
lung and a variety of cell lines [69]. An immunoreactive protein
with a slightly higher Mw, likely vG6PT, was detected in brain
and skeletal muscle microsomes [69].
G6PT is a rather hydrophobic protein embedded in the ER
membrane, its transmembrane topology is, however, still
controversial. Two models have been proposed, one with 10
[75] and the other with 12 [46,76] transmembrane alpha-helices.
Bothmodels agreewith the findings that the two extremities of the
protein are on the cytosolic side of the ER, and that the protein is
not glycosylated. Despite mammalian G6PTs are phylogeneti-
cally related to phosphoester/Pi antiporters or to G6P receptors in
bacteria/plant, they appear to operate as facilitative transporters.
G6P transport in liver microsomes is bidirectional [40,42], and
appears to be independent of the [Pi] gradient between the
microsomal lumen and the incubation medium (Fulceri and
Benedetti, unpublished data). Moreover, entrapping Pi within the
microsomal lumen (i.e. with Pb2+ [32] or Ca2+ [77] ions) does not
reduce the rate of G6P hydrolysis/transport.
The role of G6PT (or vG6PT) in G6P transport across the ER
membrane has been proven in several cell types, nevertheless,
in some cases the protein(s) facilitating G6P permeation remain
to be identified. A G6PT-independent G6P transport activity
was found in fibroblasts. It could also be detected in
microsomes of skin fibroblasts from GSD1b patients having
homozygous mutations of the G6PT gene and it was shown to
be insensitive to G6PT inhibitor chlorogenic acid [78]. Up-
regulation of the yet-unidentified transporter(s) might account
for the improvement of metabolic functions or lack of
neutrophil dysfunctions [64] observed in some GDS1b patients.
1.2. Phosphate and sulfate ions
Bidirectional transport of inorganic phosphate [Pi] across the
endo/sarcoplasmic reticulum has been repeatedly observed and
described. In the cytosol, Pi is mainly generated as the product
of ATP hydrolysis; while in the lumen of the ER, it is produced
dominantly from G6P or UDP.
The concentration of phosphate ions (i.e. HPO4
2− and
H2PO4
−) greatly influences the size of the rapidly releasable
intracellular calcium pool in a wide variety of cell types. Low
concentration of Pi, in the range reported to occur in the cytosol,
favors Ca2+ uptake and storage, via Ca2+ and Pi co-accumula-
tion, in ER vesicles derived from liver [79] and several non-
hepatic tissues [80,81].
The presence of a Pi transporter in the sarcoplasmic
reticulum (SR) membrane of mammalian skeletal muscle fibers
has been reported [82]. The Pi transporter operates by handling
Ca2+ uptake into the SR, where it has been suggested that Ca2+
and Pi co-precipitate within the lumen. Moreover, the Pi
transporter is active at physiological concentrations of myo-plasmic Pi and Ca
2+. It could be partially inhibited by
phenylphosphonic acid at concentrations that have only a
small effect on the SR Ca2+ pump, indicating that the Pi
transporter and the SR Ca2+ pump are separate proteins [83,84].
The existence of a Pi translocase in the ER membrane was
proposed in 1975 by Arion [39]. According to his model,
termed “substrate-transport model”, G6Pase enzymatic system
consists of the G6Pase enzyme and three transporters: T1, T2
and T3 mediating the traffic of G6P, Pi and glucose,
respectively. Accordingly, GSD1 was divided into four
theoretical subtypes, corresponding to defects in the G6Pase
catalytic unit (la), the G6P transporter (lb), a putative phosphate
transporter (1c), and a putative glucose transporter (1d) [85].
Pi produced from G6P could be entrapped in the lumen of
intact microsomes by forming an insoluble complex with Pb2+
ions. This provided evidence for the luminal localization of
G6Pase activity and for the substrate transport model [32]. The
observations suggested a very short (near 1 s) half-life of Pi
efflux from microsomal vesicles.
Kinetic studies performed on liver microsomes indicated the
existence of a common transporter for Pi, PPi, and carbamoyl
phosphate, which is separate from the G6P translocase [3] [3].
Nevertheless, evidence was also provided for a microsomal Pi
transport protein that does not transport PPi [86]. Permeability
of the microsomal membrane to Pi is not altered in GSD1b [45],
nor is it affected by G6P [87], supporting the independence of Pi
transporter from G6P transporter.
The molecular identity of the protein(s) involved in Pi
transport across the ER membrane is still undefined. Mamma-
lian cells contain several Pi transporters. The one present in the
inner mitochondrial membrane is a 34-kDa protein that
mediates the exchange of monobasic phosphate for OH−[88].
Pi transporters of the plasma membrane carry out Na
+-
dependent transport, and belong to at least three different
families: NaPi-I (also called NPT1), NaPi-II and NaPi-III [89].
It was reported that antibodies directed against the
mitochondrial Pi transporter cross-react with a microsomal
protein of matching size in human liver [90]. But these results
could be explained by contamination of the microsomal fraction
by mitochondrial particles.
A novel candidate for ER Pi transporter has been named
NPT4 [91]. NPT4 gene codes for a Na+/Pi co-transporter, which
belongs to the anion-cation symporter family. NPT4 is
expressed in liver and kidney and the protein is localized in
the ER membrane. Mutation in one allele of NPT4 was detected
in one case of GSD1c, and it was suggested that the diminished
G6Pase activity was due to the reduced efficiency Pi transport
across the ER membrane.
Possibility that Pi and sulfate transport could be mediated by
a common transporter has been excluded as neither Pi nor a
variety of phosphate transport inhibitors affected sulfate
transport in liver microsomes [92].
1.3. Nucleotide sugars and derivatives
Nascent polypeptides are translocated into the lumen of the
ER, where many of them undergo co- or posttranslational
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transferred to N-glycosylation sites of the native proteins is
partially synthesized on the cytosolic side of the ER membrane
as a dolichol derivative. Yet UDP-glucose (UDP-Glc) and UDP-
N-acetylglucosamine (UDP-GlcNAc) and UDP-galactose
(UDP-Gal) are substrates of luminal glycosyltransferases of
the ER. Since nucleotide sugars are synthesized primarily in the
cytosol these charged solutes must enter the ER lumen so they
can participate in protein and lipid glycosylation.
Several nucleotide sugars, such as UDP-Glc, UDP-GlcNAc,
UDP-Gal, UDP-N-acetylgalactosamine (UDP-GalNAc), UDP-
xylose (UDP-Xyl) were shown to be transported into the lumen
of microsomal vesicles prepared from rat liver and yeast.
Nevertheless, in some instances the biochemical function of the
observed transport activities in the ER is not clear. It may reflect
incomplete sorting of the corresponding Golgi proteins during
membrane biogenesis. Alternatively, it might be explained by
the overlapping ligand specificity of ER nucleotide sugar
transporters, e.g. a UDP-Glc transporter may also facilitate
UDP-Xyl and UDP-GalNAc fluxes.
Nucleotide sugar transporters (NSTs) belong to the solute
carrier family 35 (SLC35) [93]. They are hydrophobic proteins
of 320–400 amino acid residues forming ten transmembrane
helices with C- and N-terminal regions exposed to the cytosol.
NSTs are antiporters, which mediate the uptake of nucleotide
sugars from the cytosol into the lumen of the Golgi and/or the
ER in exchange for the corresponding nucleoside monopho-
sphates. According to the proposed mechanism, nucleoside
diphosphates generated by most nucleotide-sugar-dependent
glycosyltransferases are converted subsequently by nucleoside
diphosphatase activities to nucleoside monophosphates, which
serve as counter-substrates for the nucleotide sugar antiport.
However, recent studies showed that nucleotide sugar trans-
porters allow the entry of nucleotide sugars into the luminal
compartments in nucleoside-diphosphatase-deficient Sacchar-
omyces cerevisiae. Nucleoside diphosphates could exit to the
cytosol by an unknown mechanism in these mutants [94].
1.3.1. UDP-glucose
Glc3Man9GlcNAc2 structure is co-translationally transferred
to most newly synthesized polypeptides in the ER. This
oligosaccharide moiety is immediately trimmed to a “mono-
glucosylated” (GlcMan9GlcNAc2) form, which directs the
nascent protein to calnexin and calreticulin. In addition to
facilitating the folding process, these chaperones retain the
immature protein in the ER lumen until it achieves its native
conformation. The protein is detached from the chaperones
when its peripheral glucose residue is removed by glucosidase
II. If the protein has been correctly folded, it can leave the ER by
vesicular transport else it is reglucosylated by UDP-Glc
glycoprotein glucosyltransferase (UGGT), which leads to its
reassociation with calnexin and calreticulin. This mechanism
referred to as quality control prevents the release of misfolded
proteins from the ER. UGGT plays an essential role in the
process by allowing the glycoprotein to re-enter the folding
cycle. The luminal UDP-Glc consumption of UGGT [95]
requires the entry of UDP-Glc from the cytosol, which ismediated presumably by an NST protein. Although several
NSTs have been described in eukaryotes, most of them are
related to protein glycosylation and polysaccharide biosynthesis
in the Golgi apparatus, and the NST involved in supplying the
substrate for UGGT has not yet been identified.
Inward UDP-Glc transport was only functionally character-
ized in RER vesicles derived from rat liver. It was found to bear
the features of a carrier-mediated transport, such as saturation,
specificity, temperature-dependence and countertransport. Inhi-
bition and trans-stimulation studies indicated that the postulated
microsomal UDP-Glc carrier system transports other uridine
nucleotide sugars and 5′-UMP too, while cytosine or guanosine
nucleotides and non-5′-uridine monophosphates are poor
substrates [96,97]. The uptake of UDP-Glc into the lumen of
the endomembrane system was also proven by the observation
that UDP-Glc is constitutively released through the secretory
pathway from physiologically relevant tissues [98]. Tempera-
ture-dependent, substrate specific and saturable UDP-Glc
transport was also detected in ER-containing microsomes
from S. cerevisiae [99].
UDP-Gal transporter related protein 1 (UGTrel1 or
SLC35B1) [100] is a promising candidate UDP-Glc transporter
in the ER. Although the substrate specificity and subcellular
localization of human, murine and rat UGTrel1 proteins have
not been reported yet, the S. cerevisiae homologue, Hut1,
showed weak, yet significant, transport of UDP-Gal [101].
Further studies revealed that Hut1 is localized in the ER, and the
homologues from Schizosaccharomyces pombe and Arabidop-
sis thaliana transport UDP-Glc as well as UDP-Gal [102,103].
The phenotype caused by disrupted hut1 gene in fission yeast
resembles the phenotype observed in mutant cells deficient in
ER quality control proteins, which strongly suggests the role of
Hut1 in the protein processing in the ER [102].
AtUTr1, the UDP-Gal/UDP-Glc transporter from A. thali-
ana, was studied after heterologous expression in yeast. It was
shown to transport UDP-Glc 200 times faster than UDP-Gal.
The C terminus of the protein contains an ER retention signal
for membrane proteins (KKXX) [103]. The localization of the
protein was analyzed by a chimera, fusing the green fluorescent
protein to the C terminus of AtUTr1. The reticulated distribution
of AtUTr1-GFP indicated its localization in the ER rather than
in the Golgi apparatus. It should be noticed that the induction of
AtUTr1 was observed in the unfolded protein response [104].
1.3.2. UDP-galactose
The UDP-Gal supply for the galactosyltransferases partici-
pating in galactosylation of glycosphingolipids and proteins in
the Golgi lumen is ensured by an antiporter allowing the entry
of UDP-Gal and the exit of UMP [105,106]. It was reported that
UDP-Gal transport activity is exclusively localized to Golgi
fractions and absent from the ER in rat liver [107]. However,
this is contradicted by the presence of ceramide galactosyl-
transferase in the ER that requires UDP-Gal transport from the
cytosol into the lumen for the galactosylation of ceramides and
diglycerides. Ectopically expressed human UDP-Gal transpor-
ter co-operated functionally in the ER with ceramide galacto-
syltransferase enzyme either endogenous or co-expressed (in
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using subcellular fractionation and double label immunofluor-
escence microscopy that ceramide galactosyltransferase retains
UDP-Gal transporter in the ER to ensure the substrate supply
[108].
In addition – as it was discussed in the previous section –
AtUTr1 from A. thaliana was also shown to transport UDP-Gal
in the ER [104].
1.3.3. UDP-xylose
Xylosylation is involved in proteoglycan biosynthesis. UDP-
Xyl can be generated from UDP-glucuronic acid (UDP-GlcA)
within the lumen of the ER by the concerted action of UDP-
GlcA transporter and the intraluminally oriented UDP-GlcA
carboxy-lyase [109]. Nevertheless, it was suggested that UDP-
Xyl transport is not restricted to the Golgi but is also present in
the ER [106].
Investigations on permeabilized chondrocytes provided
evidence for UDP-Xyl transport into the ER. These cells can
synthesize chondroitin sulfate by utilizing UDP-Xyl either
exogenous or generated from UDP-GlcA in situ. It was
confirmed using electron microscopic autoradiography that
the incorporation of labeled xylose from exogenous UDP-[14C]
Xyl began in the ER and continued in the Golgi apparatus [109].
Comparison of RER- and Golgi-derived rat liver subcellular
fractions revealed that UDP-Xyl transport was 2–5 times faster
in the latter. Accordingly, the specific activity of xylosyltrans-
ferase was much higher in Golgi vesicles and endogenous
acceptors for xylosylation were only present in this fraction
[110].
The role of UDP-Xyl transport in the hepatic ER might be
related to glucuronidation. Addition of UDP-Xyl was shown to
stimulate UDP-glucuronosyltransferase (UGT) activity in rat
liver microsomes and in isolated permeabilized hepatocytes.
The enhanced UGT activity is due to stimulation of UDP-GlcA
uptake across the ER membrane and to elimination of the
reaction product (UDP and/or UMP) from the ER lumen. UDP-
Xyl is a remarkable trans-stimulator and a weak cis-inhibitor of
microsomal UDP-GlcA uptake. On the other hand, cytosolic
UDP-GlcA strongly trans-stimulates the efflux of UDP-Xyl,
whereas cytosolic UDP-Xyl does not trans-stimulate the efflux
of UDP-GlcA. Microsomal UDP-Xyl influx was markedly
stimulated by luminal UMP and UDP [111]. UDP-GlcA uptake
is greatly enhanced by luminal UDP-GlcNAc and UDP-Xyl in
the ER while hardly affected in Golgi vesicles [112]. The results
suggest that an antiport mechanism is involved in the UDP-Xyl
traffic across the ER membrane.
1.3.4. UDP-glucuronic acid
UDP-GlcA is synthesized in the cytosol and utilized within
the ER lumen by UGT isoenzymes in a glucuronyl group
transfer reaction called glucuronidation. UDP-GlcA is a
relatively large polar molecule with double negative charge
(phosphoryl and glucuronyl groups); hence its passive diffusion
across lipid bi-layers can be excluded. The assumptions that
glucuronidation does not require UDP-GlcA transport into the
ER lumen [110] or that this nucleotide-sugar is transported intothe ER membrane rather than into the luminal space [113] were
confuted. It was proven that UDP-GlcA traffic across the ER
membrane is a bidirectional carrier-mediated translocation
[114,115]. The carrier-mediated UDP-GlcA transport across
the ER membrane was also shown to be required and rate-
limiting for glucuronidation in intact microsomal vesicles as
well as in the intact ER of permeabilized hepatocytes [116].
The different properties of UDP-GlcA transport in ER and
Golgi derived vesicles led to the conclusion that separate carrier
proteins should exist in the two organelles [112,117]. It was also
shown that UDP-GlcA and UDP-Glc are transported via two
distinct mechanisms across the ER membrane [115]. The yet-
unidentified carrier protein can be inhibited by general anion
transport inhibitors, 4-acetamido-4′-isothiocyanostilbene-2,2′-
disulfonic acid (SITS), DIDS, probenecid [113] and by the
thiol-alkylating agent NEM administered at the cytosolic side of
the ER membrane [114,118]. Some histidyl-specific irreversible
inhibitors, especially the hydrophobic ones, such as diethyl
pyrocarbonate (DEPC) or p-bromophenacyl bromide also
inactivate the UDP-GlcA uptake [119]. Kinetic analysis of
UGT activity in intact and permeabilized microsomes indicated
that UDP-GlcNAc facilitates the transport of UDP-GlcA from
the cytosol to the ER lumen [120]. The transport was also
shown to be activated by Mg2+ and GTP (but not ATP) [117].
The kinetic properties of UDP-GlcA transport indicated the
presence of a two component UDP-GlcA transporting system in
the ER. The high affinity (Km=1.6 μM) transporter is more
sensitive to inhibition by SITS and furosemide as well as to
trans-activation by UDP-GlcNAc than the low affinity
(Km=38 μM) transporter [121].
Microsomal UDP-GlcA uptake detected by rapid filtration
technique shows a characteristic time-course. It starts with an
overshoot phase, during which luminal UDP-GlcA level
transiently exceeds the amount of UDP-GlcA present in the
vesicles at equilibrium. This phenomenon cannot be observed at
higher UDP-GlcA concentrations or after long (more than 2 h)
preincubation of the microsomes, but it can be reconstituted in
preincubated microsomal vesicles by preloading with a high
concentration (5 mM) of UDP-Glc [114]. It was concluded that
UDP-GlcA transport is trans-stimulated by a compound or
compounds contained by fresh microsomal vesicles. Accord-
ingly, UDP-GlcA release was effectively trans-stimulated by 5′-
uridine nucleotides (UDP-GlcA, UDP-Glc, UDP-GlcNAc,
UDP-Xyl, UMP, UTP) [114]. It was also demonstrated that
the transport of UDP-GlcA and some uridine nucleotides is
trans-stimulated by certain phenol glucuronides (p-nitrophenyl
glucuronide and phenolphthalein glucuronide) [122]. The
proposed antiport mechanism could co-operate with the UGTs
by exchanging cytosolic UDP-GlcA for the glucuronides
formed in the ER lumen. On the basis of mutual transport
trans-activations between various uridine nucleotides, model
systems were postulated in the ER, where UDP-GlcNAc or
UDP-Xyl functions as a shuttle compound in helping UDP-
GlcA to enter and UDP and UMP to leave the ER lumen
[111,123].
It was suggested that the oligomer complex formation of
UGT enzyme proteins in the ER membrane affects the
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facilitating UDP-GlcA uptake [124]. The UGT oligomer itself
could function as a UDP-GlcA carrier or channel [118].
However, this hypothesis is contradicted by some observations.
Firstly, the membrane-impermeant protein-modifying agent
diazobenzenesulphonate abolished the normal stimulation of
glucuronidation by UDP-GlcNAc in intact microsomes while it
only inhibited the basal rate of glucuronidation when the
membrane was permeabilized [125]. Secondly, binding studies
indicated that UGTs are not accessible to NEM or UDP-
GlcNAc, when they are in their membrane environment.
Thirdly, microsomes from UGT1-deficient Gunn rat liver
showed normal UDPGA uptake indicating that UGTs of the
1A family do not function as UDPGA carriers [126].
Collectively, a separate NEM- and diazobenzenesulphonate-
sensitive UDP-GlcA transporter might mediate the stimulation
of UGTs by UDP-GlcNAc in intact microsomes [127].
Recent findings indicate the permeability of translocon pores
abundant in the RER membrane to organic anions including
UDP-GlcA, thus it might be considered as a non-specific low-
activity UDP-GlcA permease [128].
Search of the EST database for genes related to the human
UGTrel1 revealed a novel human transporter (UGTrel7 or
SLC35D1). It was heterologously expressed in yeast cells and it
was shown to facilitate the transport of both UDP-GlcA and
UDP-GalNAc in yeast microsomes. SLC35D1 was also
transiently expressed in CHO-K1 cells, and immunostaining
indicated its co-localization with an ER marker protein. It was
therefore concluded that the novel transporter might participate
in glucuronidation by mediating the UDP-GlcA supply of UGTs
[93,129].
1.3.5. UDP-N-acetylglucosamine
UDP-GlcNAc is required for the synthesis of O- and N-
glycoproteins in the ER lumen [130]. UDP-GlcNAc transloca-
tion was observed across the membrane of vesicles derived from
rat liver RER and Golgi apparatus. The translocation is
temperature-dependent, saturable, selective, capable of trans-
stimulation, operational against a concentration gradient, and
protein-dependent (i.e. inhibited by treatment of vesicles with
proteases). The amount of vesicle-associated UDP-GlcNac at
equilibrium is directly proportional to the volume of the
vesicular space, and permeabilized microsomes are unable to
retain UDP-GlcNAc. Consequently, the microsomal uptake of
UDP-GlcNAc meets the criteria for bidirectional, carrier-
mediated translocation [107,131].
The transport of UDP-GlcNAc in the ER – similarly to that
of UDP-Xyl – may be connected to glucuronidation. It was
suggested that UDP-GlcA influx coupled to UDP-GlcNAc
efflux and UDP-GlcNAc influx coupled to UMP efflux,
combined with intravesicular consumption of UDP-GlcA,
form a mechanism that leads to the observed stimulation of
glucuronidation by UDP-GlcNAc [123].
Though UDP-GlcNAc transporter-deficient mammalian
cells have not been isolated, an aerobic milk yeast mutant
(Kluyveromyces lactis mnn2-2) was identified with this
deficiency [132], and complementation of the genetic defectled to the identification of the transporter gene [133]. Due to a
limited degree of similarity, this gene and the subsequently
identified canine and human UDP-GlcNAc transporter genes
[134,135] were assigned to different subfamilies of SLC gene
family: 35A and 35B, respectively [93]. The human UDP-
GlcNAc transporter was shown to be localized in the Golgi
membrane when expressed in CHO cells [135].
In conclusion, functional evidence supports the existence of
an ER UDP-GlcNAc transporter, while transporters with this
activity were identified at molecular level only in the Golgi.
1.3.6. UDP-N-acetylgalactosamine
The gene of a novel NST related to the human UDP-Gal
transporter-related isozyme 1 was identified by using EST
database search and named hUGTrel7. The protein was
heterologously expressed in S. cerevisiae and its transporter
function was characterized. The uptake of UDP-GlcA and
UDP-GalNAc was enhanced in the microsomes prepared from
the hUGTrel7-expressing yeast compared with the control
microsomes. It was, therefore, concluded that hUGTrel7
transports both UDP-GlcA and UDP-GalNAc [129]. The
results of double-staining immunofluorescence indicate that
hUGTrel7 is localized in the ER in mammalian cells [129], so it
may participate in glucuronidation and/or chondroitin sulfate
biosynthesis in this organelle.
1.4. Adenine nucleotides and dinucleotides
1.4.1. ATP/ADP
Chaperone-mediated protein folding in the lumen of the ER
requires ATP as an energy source. Phosphorylation of some
luminal proteins was also observed. ATP must first be
translocated across the ER membrane before it can serve as
substrate in these luminal reactions.
The transport of ATP was demonstrated in RER-derived
vesicles prepared from rat liver and canine pancreas. The
microsomes showed a saturable translocation of ATP, which
was protein mediated, since it was inhibited by treatment of
intact vesicles with pronase, NEM or DIDS. HPLC analysis and
the use of a nonhydrolyzable analog proved that the entire ATP
molecule was translocated [136]. The transport of ATP and its
inhibition by DIDS was also demonstrated in yeast ER [137].
The ATP transporters of the yeast and of rat liver ER were
reconstituted into proteoliposomes [138,139]. A 68-kDa protein
from the ER of S. cerevisiae (Sac1p) was supposed to have an
intimate role in the transport of ATP into the ER lumen [139].
However, it turned out that Sac1p is not an ATP transporter
itself but an important regulator of the transport process,
probably by controlling ER phosphoinositides. Purified Sac1p
reconstituted in proteoliposomes did not catalyze ATP uptake
[140].
In rat liver, a 56-kDa protein was identified as an ATP
transporter by photoaffinity labeling and partial purification
[141]. Transport activity of the protein could be demonstrated in
reconstitution experiments. In a more recent study ATP
transporter from rat liver RER was solubilized and reconstituted
into phosphatidylcholine liposomes. The RER proteoliposomes
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micromolar range. ATP transport was time- and temperature-
dependent, inhibited by DIDS, but was not affected by
atractyloside, a specific inhibitor of mitochondrial ADP/ATP
carrier. ATP transport was cis-inhibited strongly by ADP and
weakly by AMP. ADP-preloaded RER proteoliposomes showed
a specific increase of ATP transport activity while it was not
observed in AMP-preloaded ones. These results strongly
suggest that ATP and ADP are translocated by an antiport
mechanism across rat liver RER membrane and the transporter
is apparently different from the corresponding mitochondrial
protein [142].
1.4.2. NAD+/NADP+
Pyridine-nucleotide-dependent oxidoreductases are known
to be present in the ER lumen [25,143–146]. Accordingly, a
separate pyridine nucleotide pool was detected in ER-derived
microsomal vesicles [33,147]. Since the enzymes participating
in pyridine nucleotide biosynthesis are present in the cytosol
and mitochondria, a pyridine nucleotide transport mechanism
should be supposed. However, microsomal vesicles maintain
their luminal pyridine nucleotides for long time and the luminal
NAD(P)(H)-dependent oxidoreductase activities are latent due
to the limited access of added pyridine nucleotides to the active
sites [34,148,149]. These circumstances rule out the possibility
of a uniport-type facilitated diffusion. Further studies are
needed to clarify the transport mechanism and to identify the
transporter.
1.4.3. FAD
Protein disulfide formation is a crucial step in the folding
process of proteins that traverse the secretory pathway. A
protein relay delivers electrons from cargo proteins to oxygen
(or alternative electron acceptors) in the ER. Two major
components of the system are ER oxidoreductin 1 protein
(Ero1p) [150,151], and PDI [152].
Ero1p is an FAD-binding protein, and its activity is highly
dependent also on free FAD levels in the luminal compartment
of the ER [153]. FAD is also required for the activity of two
other proteins presumably involved in oxidative protein folding,
Erv1p and Fmo1p [154,155].
The presence of a FAD transport system in the ER membrane
is supported by ample biochemical evidence. The rapid entry of
FAD and the consequent oxidation of luminal proteins were
demonstrated in yeast microsomes [156]. Biochemical char-
acterization of FAD transport in rat liver microsomes revealed a
similar mechanism. The observed bidirectional FAD transport
did not require exogenous energy sources and was inhibited by
anion transport inhibitors and atractyloside in either direction
[157]. The FAD transport activities in yeast and mammalian
microsomes showed nearly identical kinetic characteristics. The
reported features of FAD transport suggest that the free
cytosolic FAD is allowed to equilibrate with the ER luminal
FAD pool by a facilitated diffusion.
This assumption was further supported by the identification
of flavin carrier (Flc) proteins required for FAD transport into
the ER in Candida albicans. Though Flc family exhibitsignificant sequence conservation, they do not exhibit homol-
ogy to other carrier protein families. Each Flc protein has 9–10
transmembrane domains, suggesting that these integral mem-
brane proteins can function directly as FAD transporters [158].
Despite the similar FAD transport process in yeast and
mammals and the conserved FAD-dependent oxidative protein
folding machinery, the FLC gene family is fungal-specific, i.e. its
members were detected in every fungal genome examined to date
but their homologues have not been found in other eukaryotic
genomes. Therefore, the identification of FAD transporters in
higher eukaryotic species requires further investigation.
1.5. Acetyl-CoA and carnitine
1.5.1. Acetyl-CoA
Synthesis of sialic acid or sialyl residues of gangliosides and
glycoproteins utilizes acetyl-CoA (Ac-CoA) as the donor of
acetyl group in the transfer catalyzed by acetyltransferases in
the lumen of the Golgi apparatus [159]. Therefore, Ac-CoA
synthesized in the cytosol must reach this compartment.
An Ac-CoA transporter (AT-1) was cloned in 1997. The
protein contains multiple transmembrane sequences and a
leucine zipper motif. It consists of 549 amino acids and has a
molecular mass of 60.9 kDa. Immunohistochemistry suggested
that AT-1 is expressed in the ER membrane [160]. Rat and
mouse homologues were also cloned [161,162] and the
genomic structure and promoter regions of the mouse Ac-
CoA transporter gene (slc33a1) were determined [163].
Although the tightly membrane bound and unstable transporter
protein was never purified, transmembrane hidden Markov
model (TMHMM) analysis predicts that it contains approxi-
mately 11 membrane-spanning domains [164].
Despite the highly tissue-specific distribution of acetylated
gangliosides, AT-1 is expressed ubiquitously. Two major
transcripts (3.3 kb and 4.3 kb) are present in all tissues. A
single 3.0-kb transcript is ubiquitously expressed in adult
tissues of mice, including brain [162]. The expression of AT-1 is
developmentally regulated; increased expression occurs during
early embryonic stages. To date, no human diseases involving
AT-1 have been described [165]. The AT-1 gene is highly
conserved phylogenetically, suggesting that it is particularly
significant. The precise physiological roles of this transporter
protein, however, remain to be elucidated.
1.5.2. Carnitine
Acyl-CoAs generated in the cytosol are substrates for several
metabolic pathways in mitochondria, peroxisomes and ER.
Acyl-CoA thioesters are utilized in the ER lumen by – among
others – a diacylglycerol acyltransferase that is involved in
triacylglycerol synthesis and an acyl-CoA:cholesterol acyl-
transferase involved in cholesterol metabolism. Since long
chain acyl-CoA cannot be transported directly, its acyl group is
translocated as acyl-carnitine into the above mentioned
organelles. These shuttle systems include transferase enzymes
for the transfer of acyl groups from CoA to carnitine and vice
versa, and a transporter for the translocation of acyl-carnitine
and carnitine [166]. Accordingly, carnitine acetyltransferase and
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the ER lumen [166].
Existence of transport systems for carnitine and acyl-
carnitine in the ER membrane was proposed on the basis of
microsomal experiments. The membrane of intact liver
microsomes was impermeable to palmitoyl-CoA, while both
palmitoyl-carnitine and free carnitine entered the vesicles
efficiently. The transport process was different from the
mitochondrial inner membrane carnitine/acylcarnitine exchange
carrier, since it was inhibited by mersalyl but not by NEM or
sulfobetaine [167].
The carnitine transporter was solubilized from rat liver
microsomes and reconstituted into liposomes. The reconstituted
carnitine transporter catalyzed a first-order uniport reaction
inhibited by HgCl2 and DIDS. The reconstituted transporter
also catalyzed carnitine efflux from the proteoliposomes; the
efflux was stimulated by externally added long-chain acyl-
carnitines. The most probable interpretation of this result is that
the same transporter that catalyses the uniport of carnitine may
behave as an antiporter for carnitine/long chain acyl-carnitine.
Ornithine, arginine, glutamine and lysine were also taken up by
the reconstituted liposomes, though with lower efficiency
compared to carnitine. Thus, the ER carnitine transporter may
also function as an amino acid transporter [168].
The presence of an acyl-carnitine shuttle mechanism clearly
suggests the need for an ER luminal pool of CoA. However,
questions regarding the source and maintenance of this pool in
vivo remain to be answered.
1.6. Conjugates
Some conjugated products of biotransformation need to be
transported across the ER membrane because they are produced
or cleaved by luminal enzymes. Glucuronides and sulfoconju-
gates, which are the most relevant from this aspect, are charged
at physiological pH. The existence of conjugate transporters in
the ER, therefore, can be postulated. Glucuronides generated by
UGTs leave the lumen and appear in the cytosol for being
pumped into the bile or into the blood by ABC transporters of
the plasma membrane. On the other hand, the entry of
glucuronides in the ER might also have biochemical impor-
tance, as they can be hydrolyzed by the luminal β-glucur-
onidase [169]. Although no specific disease is known to be
associated with the defective transport of glucuronides across
the ER membrane, such abnormality was detected in a
jaundiced patient [170]. Accumulation of newly synthesized
bilirubin glucuronide was found in the lumen of liver
microsomes prepared from the patient. Moreover, the same
liver microsomes released 1-naphthol glucuronide at normal
rate. It was concluded that the ER export might be regulated by
specific transporters and play a role in the sorting of
glucuronides, destined for export through bile canalicular or
basolateral plasma membranes [170]. The presence of a protein-
mediated, facilitated glucuronide traffic was further supported
by the observation that bilirubin diglucuronide is able to cross
native microsomal membranes in contrast to model ER
phospholipid membranes [171].It was found in rat liver microsomes that the membrane
traffic of certain phenol-glucuronides is mutually trans-
stimulated by UDP-GlcA. It was, therefore, suggested that an
antiport mechanism can assist the UGTs by allowing the entry
of a substrate (UDP-GlcA) in exchange for the product
(glucuronide) of the enzyme [122]. A protein mediated transport
of estradiol glucuronide was demonstrated in rat liver micro-
somes. The transport was shown to be bi-directional, time- and
temperature-dependent and it could be inhibited by DIDS. The
lack of ATP- or glutathione-dependence indicated that this
mechanism is distinct from the glucuronide transporters of the
plasma membrane. Cis-inhibition of the unknown ER transpor-
ter suggested that its substrate specificity was directed toward
selected sulfo- and glucuronoconjugates [172]. Competitive
inhibition between various glucuronides for microsomal trans-
port was further investigated with direct transport measure-
ments. The collected data suggest the existence of multiple
glucuronide transporters of overlapping specificities. The main
determinant of the glucuronide binding to the transporter seems
to be the size of the aglycone [173].
Similarly to glucuronides, sulfoconjugates, especially those
of steroid hormones must be translocated from the cytosol in the
ER lumen to have access to an enzyme’s active site. Steroid
sulfatase (STS) – also called arylsulfatase C (ARSC) or estrone
sulfatase (ES) – has a mushroom-like tertiary structure with a
transmembrane stem and a luminal cap that contains the catalytic
site near the internal surface of the ER membrane [174].
It is possible that the hydrophobic deconjugated products of
STS (e.g. steroid hormones) and even the sulfated substrates can
cross the membrane through a hydrophobic tunnel formed by
the two transmembrane helices of the enzyme. Nevertheless, the
sulfoconjugate transporter of the ER membrane has not been
identified.
1.7. Oligopeptides
1.7.1. Glutathione
Redox environment of the ER lumen is of great importance
for the oxidative folding of secretory proteins. Glutathione
(GSH) and glutathione disulfide (GSSG) constitute the most
important redox buffer of animal cells both in the cytosol and in
organelles. The ratio of (GSH)/(GSSG) in the cytosol is 30–
100:1 resulting in a redox potential of about −230 mV. The
lumen of the ER is more oxidized (−180 mV) with a 1–3:1 ratio
of (GSH)/(GSSG) [175]. The high proportion of the total
population of glutathione was found to be in mixed disulfides
with proteins, which may play role as a GSH reserve and as a
component of a redox buffering system [176]. Two possible
mechanisms were presumed to maintain the oxidative environ-
ment of the ER lumen. The first is the preferential uptake of
GSSG, or the efflux (or exocytosis) of the reduced form.
Alternatively, ER-resident enzymes could produce oxidizing
compounds in the lumen.
Investigation of the microsomal transport of the redox couple
supported the second possibility. A bi-directional, saturable
GSH transport was found in rat liver microsomal vesicles, which
could be inhibited by the anion transport blockers flufenamic
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was metabolized to GSSG in the lumen. Microsomal membrane
was virtually impermeable to GSSG. This result was contrary to
previous findings indicating the preferential transport of GSSG
[175], which can be explained by the preparation and storage of
microsomes in a reducing buffer.
Rapid permeation of GSH and GSSG across SR membrane
was demonstrated in skeletal muscle. It was also proved that the
local redox potential regulate ryanodine receptor type 1 (RyR1)
due to the alterations in the oxidation state of its hypersensitive
thiol groups. Thiol oxidation by reactive oxygen species,
GSSG, and other thiol reagents activate, while reducing agents,
such as GSH, dithiothreitol and mercaptoethanol inhibit the
channel. Accordingly, RyR1 from skeletal muscle can function
as a transmembrane redox sensor and the transport of GSH/
GSSG is involved in regulating of this channel [178]. It was
found that GSH transport across ER/SR membrane correlated
with the abundance of RyR1. The transport was fastest in
muscle terminal cisternae, fast in muscle microsomes and slow
in liver, heart and brain microsomes. GSH influx could be
inhibited by RyR1 blockers, and the inhibitory effect was
counteracted by RyR1 agonists [179]. These results suggest that
RyR1 may act as glutathione transporter on its own, or may
interact with a putative GSH/GSSG transporter. The uptake of
radiolabeled GSH into SR vesicles was demonstrated, using an
improved rapid-filtration assay where intravesicular glutathione
was trapped by the efflux blocker lanthanum chloride. The
uptake could be blocked by RyR inhibitor ruthenium red and
ryanodine. An SR-like GSH transport appeared in microsomes
obtained from a HEK-293 cell line transfected with RyR1 [180].
These observations strongly suggest that RyR1 itself mediates
GSH transport through the SR membranes of skeletal muscle.
1.7.2. Antigenic oligopeptides
The peptides needed for antigen presentation are generated
by the proteasome complex in the cytosol. They need to be
transported into the ER lumen where they are further processed
and loaded onto major histocompatibility complex (MHC) class
I molecules before they are finally displayed on the cell surface.
The macromolecular peptide-loading complex [181] contains
the transporter associated with antigen processing (TAP) that
mediates the entry of antigenic peptides into the lumen of the
ER [182]. TAP is a heterodimer of TAP1 and TAP2 and belongs
to the ATP-binding casette superfamily [183]. Each subunit
contains a transmembrane domain that binds to oligopeptides
and forms the translocation pore, and a cytosolic nucleotide-
binding domain which provides energy for translocations by
ATP hydrolysis [182]. Expression of TAP – as a key factor of
antigen presentation – is upregulated during infection. How-
ever, tumors and viruses may escape immune surveillance by
suppressing TAP function [184].
2. Non-specific transport in the ER
It has been repeatedly observed that microsomal vesicles
derived from the ER exhibit a basal permeability to various
compounds – including xenogenous molecules – whichpresumably do not have strictly specific transporters. A variety
of structurally unrelated compounds is (or should be) able to
cross the ER membrane, but only a few transporters have been
reported so far [185]. This non-specific permeability is usually
attributed to the damage or to the improper orientation of the
membrane. However, recent observations indicate the role of
translocon protein channel in the permeation of small molecules
across the ER membrane.
Co-translational protein translocation and integration into the
membrane of the ER occur at sites termed translocon (for a
review, see [186]). This pore is formed by the heterotrimeric
protein complex Sec61αβγ that forms an aqueous pore. This is
the largest pore in the ER membrane, with an estimated
diameter of 40–60 Å in the ribosome-bound state and a smaller
diameter of 9–15 Å in the ribosome-free state [187].
The tight ribosome-channel junction on the cytosolic side
can prevent the passage of small molecules. In addition, the
permeability of the pore is regulated by the luminal chaperone
BiP. The structure of the pore was elucidated by X-ray
crystallography, which revealed a permeability barrier inside
the channel. The channel has an hourglass shape, and a small á-
helical segment seems to act as a plug, which is removed (i.e.
the pore is opened) by the binding of ribosomes [188].
A recent report demonstrated the persistent binding of
ribosomes after termination of translocation. Thus, the ER
membrane might contain a large number of ribosome-bound
translocons with their pores unoccupied by polypeptides [189].
In this empty state, the complex seems to allow the passage of
small molecules.
Electrophysiological studies, using pancreatic rough micro-
somes, demonstrated that polarized molecules like glutamate
and 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid
(HEPES) can permeate the translocon channel. A large increase
in membrane conductance was detected after addition of
puromycin, an antibiotic that releases nascent polypeptide
chains from the ribosomes [190].
It was proved with fluorescent probes that secretory proteins
are in an aqueous milieu when undergoing translocation across
the translocon channels [191]. The pore size was determined by
applying fluorescent quenchers of different sizes, and it was
shown that I− and NAD+ can cross the channel [192].
The permeation of a small neutral molecule, 4-methyl-
umbelliferyl-α-D-glucopyranoside was tested by measuring the
rate of its hydrolysis in the ER. The reaction is catalyzed by a
luminal α-glucosidase, hence, it is dependent on the substrate's
entry into the ER. The basal entry of the dye into the ER of
Chinese hamster ovary-S cells was increased by the addition of
puromycin and pactamycin [193,194]. This effect was inhibited
by cycloheximide, an elongation and release inhibitor antibiotic
[194]. It was concluded that translocon channels are permeable
to 4-methyl-umbelliferyl-α-D-glucopyranoside as long as empty
ribosomes remain bound to them.
The role of translocon pores in the basal Ca2+ leak from the
ER was studied in pancreatic acinar cells, and a puromycin-
induced Ca2+ efflux was found [195]. It was also demonstrated
that puromycin depletes the ER calcium store and this effect
could be prevented by anisomycin, an inhibitor of peptidyl
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was further evidenced, and it was demonstrated that this leakage
can activate the store-operated Ca2+ channels, which suggests
the possibility of a translocon-related calcium signaling [197].
Contribution of translocon peptide channel to the permeation
of low molecular mass anions, such as UDP-GlcA was also
demonstrated in rat liver microsomes. Puromycin increased the
activity of the luminal UGTs in intact rough, but not in smooth
microsomes. This effect could be inhibited by pretreatement with
anisomycin or an antibody against Sec61 translocon component.
It was concluded that translocons may take part in the substrate
supply of luminal enzymes, in the transport of various
xenobiotics, FAD and exogenous biotin derivatives [128].
3. Conclusion
Main metabolic functions of the ER, such as glucose
production, pre-receptorial steroid reactivation (including corti-
sone reduction and steroid sulfate hydrolysis), glucuronidation
and deglucuronidation, protein synthesis, oxidative folding and
glycosylation, antigen processing and presentation, are all
associated to transmembrane traffic ofmetabolites. It is, therefore,
doubtless that characterization of ER transport is indispensable for
the understanding of ER biochemistry. All transport activities
studied so far have been found to be protein-mediated. Moreover,
competition-patterns and comparison of inhibitor-profiles often
indicate that the studiedmolecules are not transported by the same
protein.Nevertheless, it cannot be excluded that ER transporters–
similarly to several ER enzymes – are specific to a group of
molecules sharing common structural features rather than to a
particular compound. In other terms, the large number of
observed transport activities might be attributed to a few proteins
with wide and perhaps overlapping substrate ranges. Identifica-
tion of these ER transporters is a major goal of on-going
investigation. Hopefully, the progress in this field will be
accelerated by the recent development in molecular biology
techniques and by the growing protein and nucleic acid databases.
Cloning and sequencing of G6PT and TAP subunits were major
achievements that not only revealed the pathomechanism of
GSD1b and certain immunologic diseases but also inspired
further research of the compartmentalized metabolism of the ER.
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